Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

STAT

DECEMBER 5, 2023

Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Plenty of people in pharma and at the banks that invest in it seem to think so. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

Drug Pricing 318

Drug Pricing Drug Development 318

STAT

DECEMBER 13, 2024

Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 254

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 254

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Definitive Healthcare

FEBRUARY 23, 2024

Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToShow":2,

Drug Pricing 52

Drug Pricing Hospitals Drug Development 52